tiprankstipranks
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
US Market
CRVS
Corvus Pharmaceuticals
RESEARCH TOOLSreports
Want to see CRVS full AI Analyst Report?

Corvus Pharmaceuticals (CRVS) Stock News & Sentiment

694 Followers
Corvus Pharmaceuticals Announces Board Changes and New Director
Premium
Company Announcements
Corvus Pharmaceuticals Announces Board Changes and New Director
7d ago
8K
CRVS
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
Premium
Company Announcements
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
2M ago
CRVS
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
Premium
Company Announcements
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
2M ago
8K
CRVS
Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
Premium
Ratings
Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
2M ago
CRVS
Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
Premium
Company Announcements
Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
2M ago
CRVS
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch
Premium
Company Announcements
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch
2M ago
CRVS
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CRVS
More CRVS News >

CRVS News on the Web

Corvus Pharmaceuticals (CRVS) Gains Momentum with Buy Rating from Goldman Sachs
GuruFocus News
Bullish
This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says
CNBC
Neutral
Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls
TipRanks News
Neutral
Here are Friday's biggest analyst calls: Nvidia, Apple, Netflix, JPMorgan, Affirm, UnitedHealth, WeRide & more
CNBC
Neutral
Analysts’ Top Healthcare Picks: Corvus Pharmaceuticals (CRVS), Rhythm Pharmaceuticals (RYTM)
TipRanks News
Bullish
Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs
TipRanks News
Bullish
Mizuho Securities Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)
TipRanks News
Bullish
Barclays Sticks to Their Buy Rating for Corvus Pharmaceuticals (CRVS)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
CRVS
Sector Average
Media Buzz
This Week6 articles
Weekly Average0 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CRVS’s Media Buzz Sentiment?
Currently, no data Available
What is CRVS’s weekly average amount of articles?
Currently, no data Available
What is CRVS’s News Sentiment?
100% of articles about CRVS were positive this week, compared to its sector average of 70%.
    Healthcare Stocks that are Trending in the News
    TVTXTravere Therapeutics
    HVOOpen Orphan Plc
    PBMPsyence Biomedical
    QDELQuidelOrtho
    Showing the stocks with the most bullish news sentiment over the past week